Spin-out company ReactivLab is to commercialise the new animal health diagnostic technology developed in the University’s Faculty of Veterinary Medicine. ReactivLab will provide services and kits that can detect sub-clinical symptoms of inflammation, infection and disease in both companion and farm animals. These tests can allow pet owners or farmers to know if their animal is unwell before any visible symptoms appear enabling early intervention with the best treatment.
IP Group plc, the intellectual property commercialisation company, has invested £450,000 in ReactivLab Ltd for a 33.2% stake.
ReactivLab’s new diagnostic approach exploits blood proteins known as acute phase proteins (APPs). Acute phase proteins (APP) are a group of blood proteins that change in concentration in animals subjected to challenges such as infection, inflammation, surgical trauma or stress. Quantification of their concentration can provide diagnostic and prognostic information. The university have identified specific APPs (and combinations) that act as biomarkers to detect the presence of disease or poor health before visible symptoms appear.
Professor David Eckersall, scientific founder of ReactivLab, is a world-leading researcher in the area of acute phase proteins in animals co-ordinating the European Concerted Action Group on Acute Proteins in Animals. He has specialised in this field for over 20 years and has presented the findings of his work at international scientific meetings throughout the world. He is a Professor of Veterinary Biochemistry at the Faculty of Veterinary Medicine at the University of Glasgow and has been responsible for many of the major advances in monitoring the APP response in domestic animals such as dogs, cats, cattle and pigs. He has also invented novel methods for analysis and discovered new applications for the diagnostic use of APP showing the benefit of measuring the proteins in a variety of conditions including bovine mastitis and pneumonia, feline infectious peritonitis and canine leukaemia.
ReactivLab will exploit this research and provide services in diagnostic testing for acute phase proteins. For example, blood samples from dogs and cats can be analysed to assist in the very early diagnosis of diseases such as arthritis, cancer and various infectious diseases. Diagnostic kits are also planned to make the approach available world-wide.
APP testing will not only give the opportunity for vets to intervene with treatments before a condition has advanced significantly they will also provide animal owners with a means to monitor animal health on a regular basis.
ReactivLab is the third spin-out from IP Group’s partnership with the University of Glasgow which was announced in October 2006. The first two companies from the collaboration are XanIC Limited, which is commercialising a new semiconductor process technology, and Wireless bioDevices Limited, which was established to commercialise wireless sensor technology for use in medical diagnostics.
The diagnostic test technology has already received Synergy Fund investment via a £200,000 loan from the Fund to the University for pre-incorporation development. Synergy Fund is a Glasgow/Strathclyde university Fund managed by Scottish Equity Partners (SEP). ReactivLab has also received a Scottish Executive SMART Award.
Alan Aubrey, Chief Executive of IP Group, said: “We are delighted with the progress being made at Glasgow. ReactivLab is the first spin-out we have completed in the exciting and growth area of animal health but is the third spin-out from Glasgow within the first year that IP Group partnered with the University.”
Prof Steve Beaumont, VP Research & Enterprise, commented: “The University is very pleased that research carried out on our internationally renowned Faculty of Veterinary Medicine has led to a spinout that will assist in the diagnosis of diseases in animals. This substantial investment from IP Group in addition to earlier support from the Synergy Fund recognises the confidence we have in the future success of the business. As we expected our collaboration with IP Group has accelerated our spin-out process and we are delighted to announce the formation of a third company so soon after our partnership was launched.”
Prof David Eckersall, Director, ReactivLabs, said: “Establishing ReactivLab will allow the acute phase protein tests to become widely available so that instead of being restricted to our research programmes their full benefit in being able to detect even sub clinical disease in dogs and cats will be available to the pet owning community at large.”
Martin Shannon | alfa
Energy crop production on conservation lands may not boost greenhouse gases
13.03.2017 | Penn State
How nature creates forest diversity
07.03.2017 | International Institute for Applied Systems Analysis (IIASA)
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy